california tirzepatide Get in | Personalized GLP-1 Therapy Tirzepatide | Wellness Center in

The exception: in March 2024, the FDA approved a supplemental indication for semaglutide 2.4 mg (Wegovy) to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with established cardiovascular disease and either obesity or overweight (SELECT trial, Lincoff et al., New England Journal of Medicine 2023)

This is why many doctors now look at more sensitive tests

As diabetes research continues to evolve, semaglutide is poised to play a pivotal role in future management strategies

The researchers emphasized the need for public education, healthcare provider training, and the implementation of stigma-reduction programs that would be supportive of people seeking treatment for obesity